Vésale Bioscience

Our mission is to deliver evidence-driven, personalized therapies that combat difficult-to-treat and antimicrobial-resistant infections

Restoring hope for patients with no remaining options and broadening access to life-changing care.

About Phage Therapy
Our mission

Vésale Bioscience

Stem from our advanced R&D on bacteriophages, our Mission is to develop robust modern solutions to fight antimicrobial-resistant infections.

Antimicrobial resistance (AMR) are a substantial public health issue. From around 1.3 million deaths a year today, the AMR burden is expected to reach ten million/y deaths by 2050, more than cancer.

Our approach is to work on personalized, selective, and specific phage therapies against those multi-resistant bacterial infections.

Vésale Bioscience named most innovative start-up in life sciences in Europe at tenth edition of BioFIT
The European Innovation Council’s Acceleration Fund has awarded Vesale Bioscience €1.8M in 2023

INTERESTED IN SOLVING THE PROBLEM OF ANTIMICROBIAL RESISTANCE (AMR)

Know more

Vésale Bioscience in the press

They talk about us.

O.A.G. (UK)

Vésale Bioscience, a pioneer in the development of innovative, personalized and sustainable phage-based therapy solutions for tackling superbugs and antimicrobial resistance.

L’Écho

Vésale Bioscience named most innovative start-up in life sciences in Europe at tenth edition of BioFIT

La Libre

Vésale Bioscience enters into an innovative and ambitious collaboration with the Belgian Army
Our daily life

Latest news

Don’t miss any important events or news about Vésale Bioscience.

Know more